FY2024 Earnings Forecast for FATE Issued By Leerink Partnrs
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Investment analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Fate Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will earn ($1.62) per share for the year. The consensus estimate for […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Investment analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Fate Therapeutics in a note issued to investors on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the biopharmaceutical company will earn ($1.62) per share for the year. The consensus estimate for […]
